Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Mutation of the RB-1 and p53 tumor suppressors is associated with the development of human osteosarcoma. With the goal of generating a mouse model of this disease, we used conditional and transgenic mouse strains to inactivate Rb and/or p53 specifically in osteoblast precursors. The resulting Rb;p53 double mutant (DKO) animals are viable but develop early onset osteosarcomas with complete penetrance. These tumors display many of the characteristics of human osteosarcomas, including being highly metastatic. We established cell lines from the DKO osteosarcomas to further investigate their properties. These immortalized cell lines are highly proliferative and they retain their tumorigenic potential, as judged by their ability to form metastatic tumors in immunocompromised mice. Moreover, they can be induced to differentiate and, depending on the inductive signal, will adopt either the osteogenic or adipogenic fate. Consistent with this multipotency, a significant portion of these tumor cells express Sca-1, a marker that is typically associated with stem cells/uncommitted progenitors. By assaying sorted cells in transplant assays, we demonstrate that the tumorigenicity of the osteosarcoma cell lines correlates with the presence of the Sca-1 marker. Finally, we show that loss of Rb and p53 in Sca-1-positive mesenchymal stem/progenitor cells is sufficient to yield transformed cells that can initiate osteosarcoma formation in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“For example, it has been shown that acute myeloid leukemia can arise from a committed progenitor cell (23).”
BackgroundJonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053
Rodda, S. J., & McMahon, A. P. (2006) · Development · doi:10.1242/dev.02480 · Cited by 1,010
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
Age-Related Changes in Trabecular Architecture Differ in Female and Male C57BL/6J Mice
Glatt, V., Canalis, E., Stadmeyer, L., & Bouxsein, M. L. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070507 · Cited by 606
Self-citationAcute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry
Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wysocki, J. M., & Jacks, T. (2003) · Nature · doi:10.1038/nature01764 · Cited by 538 · cited 11×
“The Rb /c;p53c/c;Cre and Rbc/c;p53 /c; Cre genotypes were highly predisposed to develop osteosarcoma, and their mean survival time was considerably shorter than that of the p53c/c;Cre animals (Fig.”
BackgroundMethodInfluentialMesenchymal Stem Cell Features of Ewing Tumors
Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P., & Delattre, O. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.027 · Cited by 507
Cooperative tumorigenic effects of germline mutations in Rb and p53
Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., & Jacks, T. (1994) · Nature Genetics · doi:10.1038/ng0894-480 · Cited by 368
Self-citationThomas, D. M., Carty, S. A., Piscopo, D. M., Lee, J.-S., Wang, W.-F., Forrester, W. C., & Hinds, P. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00327-6 · Cited by 361
Molecular Pathogenesis of Osteosarcoma
Kansara, M., & Thomas, D. M. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0505 · Cited by 273
Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling
Lengner, C. J., Steinman, H. A., Gagnon, J., Smith, T. W., Henderson, J. E., Kream, B. E., Stein, G. S., Lian, J. B., & Jones, S. N. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200508130 · Cited by 265
A review of clinical and molecular prognostic factors in osteosarcoma
Clark, J. C. M., Dass, C. R., & Choong, P. F. M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0330-x · Cited by 250
Mukherjee, S., Raje, N., Schoonmaker, J. A., Liu, J. C., Hideshima, T., Wein, M. N., Jones, D. C., Vallet, S., Bouxsein, M. L., Pozzi, S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33102 · Cited by 238
Self-citationWang, X., Kua, H.-Y., Hu, Y., Guo, K., Zeng, Q., Wu, Q., Ng, H.-H., Karsenty, G., de Crombrugghe, B., Yeh, J., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507106 · Cited by 225
Toguchida, J., Ishizaki, K., Sasaki, M. S., Ikenaga, M., Sugimoto, M., Kotoura, Y., & Yamamuro, T. (1988) · PubMed · Cited by 206
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.467 · Cited by 199
Tsuchiya, T., Sekine, K.-I., Hinohara, S.-I., Namiki, T., Nobori, T., & Kaneko, Y. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00255-1 · Cited by 179
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 155
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Gokgoz, N., Parkes, R., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 141
Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130
Dannenberg, J.-H., Schuijff, L., Dekker, M., van der Valk, M., & Riele, H. T. (2004) · Genes & Development · doi:10.1101/gad.322004 · Cited by 137 · cited 1×
“It seems likely that other pocket proteins contribute to this suppression, becausee chimeras generated with Rb;p107, but not Rb, mutant ES cells develop osteosarcomas at low frequency (22).”
BackgroundComparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
Gokgoz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8<2181::aid-cncr1561>3.0.co;2-3 · Cited by 125
Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells
Tataria, M., Quarto, N., Longaker, M. T., & Sylvester, K. G. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2005.12.001 · Cited by 85
Berman, S. D., Yuan, T. L., Miller, E. S., Lee, E. Y., Caron, A. M., & Lees, J. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0176 · Cited by 83
Self-citationDevelopmental defects and tumor predisposition in Rb mutant mice
Vooijs, M., & Berns, A. J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202999 · Cited by 82
Li-Fraumeni Syndrome: a p53 Family Affair
Iwakuma, T., Lozano, G., & Flores, E. R. (2005) · Cell Cycle · doi:10.4161/cc.4.7.1800 · Cited by 63
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Prockop, D. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.62 · Cited by 577
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Rb regulates fate choice and lineage commitment in vivo
Calo, E., Quintero-Estades, J. A., Danielian, P. S., Nedelcu, S., Berman, S. D., & Lees, J. A. (2010) · Nature · doi:10.1038/nature09264 · Cited by 314
Self-citationBone Microenvironment and Osteosarcoma Metastasis
Yang, C., Tian, Y., Zhao, F., Chen, Z., Su, P., Li, Y., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196985 · Cited by 291
Metadata
- Authors
- Berman, S. D., Calo, E., Landman, A. S., Danielian, P. S., Miller, E. S., West, J. C., Fonhoue, B. D., Caron, A., Bronson, R., Bouxsein, M. L., Mukherjee, S., & Lees, J. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-08-19
- Volume
- 105
- Issue
- 33
- Pages
- 11851-11856
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1991255873
- Cited by
- 266
- References
- 26
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.